177 related articles for article (PubMed ID: 24035882)
1. Loss of bacillus Calmette-Guérin viability adversely affects the direct response of urothelial carcinoma cells to bacillus Calmette-Guérin exposure.
Shah G; Zhang G; Chen F; Cao Y; Kalyanaraman B; See W
J Urol; 2014 Mar; 191(3):823-9. PubMed ID: 24035882
[TBL] [Abstract][Full Text] [Related]
2. H2O2 generation by bacillus Calmette-Guérin induces the cellular oxidative stress response required for bacillus Calmette-Guérin direct effects on urothelial carcinoma biology.
Shah G; Zielonka J; Chen F; Zhang G; Cao Y; Kalyanaraman B; See W
J Urol; 2014 Oct; 192(4):1238-48. PubMed ID: 24928267
[TBL] [Abstract][Full Text] [Related]
3. A synthetic polyvalent ligand for α5β1 integrin activates components of the urothelial carcinoma cell response to bacillus Calmette-Guérin.
Chen F; Zhang G; Cao Y; Wakim B; See WA
J Urol; 2013 Mar; 189(3):1104-9. PubMed ID: 22999999
[TBL] [Abstract][Full Text] [Related]
4. MB49 murine urothelial carcinoma: molecular and phenotypic comparison to human cell lines as a model of the direct tumor response to bacillus Calmette-Guerin.
Chen F; Zhang G; Cao Y; Hessner MJ; See WA
J Urol; 2009 Dec; 182(6):2932-7. PubMed ID: 19853870
[TBL] [Abstract][Full Text] [Related]
5. The Dose-Response Relationship of bacillus Calmette-Guérin and Urothelial Carcinoma Cell Biology.
Shah G; Zhang G; Chen F; Cao Y; Kalyanaraman B; See WA
J Urol; 2016 Jun; 195(6):1903-10. PubMed ID: 26694905
[TBL] [Abstract][Full Text] [Related]
6. HMGB1 release by urothelial carcinoma cells in response to Bacillus Calmette-Guérin functions as a paracrine factor to potentiate the direct cellular effects of Bacillus Calmette-Guérin.
Zhang G; Chen F; Cao Y; Amos JV; Shah G; See WA
J Urol; 2013 Sep; 190(3):1076-82. PubMed ID: 23353043
[TBL] [Abstract][Full Text] [Related]
7. Bacillus Calmette-Guerin inhibits apoptosis in human urothelial carcinoma cell lines in response to cytotoxic injury.
Chen F; Zhang G; Cao Y; Payne R; See WA
J Urol; 2007 Nov; 178(5):2166-70. PubMed ID: 17870116
[TBL] [Abstract][Full Text] [Related]
8. Contributors to HMGB1 release by urothelial carcinoma cells in response to bacillus Calmette-Guérin.
Zhang G; Chen F; Cao Y; See WA
J Urol; 2013 Oct; 190(4):1398-403. PubMed ID: 23583857
[TBL] [Abstract][Full Text] [Related]
9. HMGB1 release by urothelial carcinoma cells is required for the in vivo antitumor response to Bacillus Calmette-Guérin.
Zhang G; Chen F; Cao Y; Johnson B; See WA
J Urol; 2013 Apr; 189(4):1541-6. PubMed ID: 23041342
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder.
Sylvester RJ; Brausi MA; Kirkels WJ; Hoeltl W; Calais Da Silva F; Powell PH; Prescott S; Kirkali Z; van de Beek C; Gorlia T; de Reijke TM;
Eur Urol; 2010 May; 57(5):766-73. PubMed ID: 20034729
[TBL] [Abstract][Full Text] [Related]
11. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE
Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
[TBL] [Abstract][Full Text] [Related]
12. Randomized controlled trial of oxybutynin extended release versus placebo for urinary symptoms during intravesical Bacillus Calmette-Guérin treatment.
Johnson MH; Nepple KG; Peck V; Trinkaus K; Klim A; Sandhu GS; Kibel AS
J Urol; 2013 Apr; 189(4):1268-74. PubMed ID: 23123375
[TBL] [Abstract][Full Text] [Related]
13. Randomized Controlled Study of the Efficacy, Safety and Quality of Life with Low Dose bacillus Calmette-Guérin Instillation Therapy for Nonmuscle Invasive Bladder Cancer.
Yokomizo A; Kanimoto Y; Okamura T; Ozono S; Koga H; Iwamura M; Tanaka H; Takahashi S; Tsushima T; Kanayama HO; Akaza H; Shinohara N; Mugiya S; Nomata K; Nakamura T; Naito S
J Urol; 2016 Jan; 195(1):41-6. PubMed ID: 26307162
[TBL] [Abstract][Full Text] [Related]
14. The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study.
Colombel M; Saint F; Chopin D; Malavaud B; Nicolas L; Rischmann P
J Urol; 2006 Sep; 176(3):935-9. PubMed ID: 16890660
[TBL] [Abstract][Full Text] [Related]
15. Bacillus Calmette-Guérin with or without interferon α-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer.
Nepple KG; Lightfoot AJ; Rosevear HM; O'Donnell MA; Lamm DL;
J Urol; 2010 Nov; 184(5):1915-9. PubMed ID: 20846688
[TBL] [Abstract][Full Text] [Related]
16. Connaught and Russian strains showed the highest direct antitumor effects of different Bacillus Calmette-Guérin substrains.
Secanella-Fandos S; Luquin M; Julián E
J Urol; 2013 Feb; 189(2):711-8. PubMed ID: 22982433
[TBL] [Abstract][Full Text] [Related]
17. Factors affecting response to bacillus Calmette-Guérin plus interferon for urothelial carcinoma in situ.
Rosevear HM; Lightfoot AJ; Birusingh KK; Maymí JL; Nepple KG; O'Donnell MA;
J Urol; 2011 Sep; 186(3):817-23. PubMed ID: 21788050
[TBL] [Abstract][Full Text] [Related]
18. T1 Substaging of Nonmuscle Invasive Bladder Cancer is Associated with bacillus Calmette-Guérin Failure and Improves Patient Stratification at Diagnosis.
de Jong FC; Hoedemaeker RF; Kvikstad V; Mensink JTM; de Jong JJ; Boevé ER; van der Schoot DKE; Zwarthoff EC; Boormans JL; Zuiverloon TCM
J Urol; 2021 Mar; 205(3):701-708. PubMed ID: 33191862
[TBL] [Abstract][Full Text] [Related]
19. Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results.
Kelley DR; Ratliff TL; Catalona WJ; Shapiro A; Lage JM; Bauer WC; Haaff EO; Dresner SM
J Urol; 1985 Jul; 134(1):48-53. PubMed ID: 3892051
[TBL] [Abstract][Full Text] [Related]
20. Clinical and Preclinical Therapies for Bladder Cancer Following Bacillus Calmette-Guérin Failure.
Nazmifar M; Williams C; Naser-Tavakolian A; Heard J; Rosser C; Theodorescu D; Ahdoot M
J Urol; 2023 Jan; 209(1):32-48. PubMed ID: 36067380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
